数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of substantia nigra dopaminergic neurons and subsequent striatal dopamine depletion, resulting in cardinal motor symptoms including resting tremor, rigidity, bradykinesia, and postural instability.
方法
Particle Size, Polydispersity Ind] The colloidal characteristics of the Mexil-loaded niosomal dispersions were measured as mean hydrodynamic diameter, polydispersity index (PDI), and zeta potential using Zetasizer Nano ZS (Malvern Instruments, Malvern Instruments Ltd., Malvern, Worcestershire, UK) at 25 °C.；Each formulation was measured in three replicates, and the results are represented as mean ± standard deviation (SD; n = 3) [78].；Samples were evaluated at 1, 3, and 6 months for PZ, ZP, PDI, and the percentage of entrapped Mexil in the niosomal formulation.；Animals] In a controlled environment with a constant temperature of 23 ± 2 °C, a 12 h light/dark cycle, and a humidity of 50 ± 10%, adult male Sprague–Dawley rats weighing an average of 200–250 g were maintained (4 rats/cage).
核心结论
Formulations prepared with higher lecithin content (225 mg; N4–N6) were found to have significantly higher EE% (84.2–93.0%) than those with 150 mg of lecithin (58.0–71.0%).；Among all of the formulations, N4 showed the highest EE% (93.0 ± 1.7%), followed by N6 (89.1 ± 2.6%) and N5 (84.2 ± 1.5%). ‖ 结论：Overall, our results suggest that niosomal Mexil exerts robust neuroprotective effects against rotenone-induced Parkinsonism-like neurodegeneration by acting on the co-regulation of oxidative stress, inflammation, mitochondrial dysfunction, autophagy, and apoptosis.
局限
全文未设独立 limitations 节；结构上为非 RCT 设计，因果推断强度受限。
对本项目的价值
★★★☆☆ 线粒体端点既是机制解释层，也是最容易拿到体外 / 影像读数的中间层。命中核心 mTOR/AMPK；最大样本量约 12。
全文来源
PMC JATS 全文（正文 69,462 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Niosomal Mexiletine Attenuates Rotenone-Induced Parkinsonism via Modulation of the circDLGAP4/miR-134-5p/p-CREB Axis and Restoration of Mitochondrial-Autophagic Homeostasis.
- 期刊与标识：Pharmaceuticals (Basel) · PMID 42943351 · DOI 10.3390/ph19101654**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。